Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)
China · Delayed Price · Currency is CNY 20.87
+0.19 (0.92%)
Feb 4, 2026, 3:00 PM CST
SHA:603538 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,536 | 1,368 | 1,209 | 1,440 | 1,245 | 1,190 |
Other Revenue | 4.66 | 4.66 | 7.79 | 17.37 | 13.47 | 3.37 |
| 1,541 | 1,373 | 1,216 | 1,457 | 1,258 | 1,193 | |
Revenue Growth (YoY) | 24.54% | 12.85% | -16.51% | 15.80% | 5.43% | 1.12% |
Cost of Revenue | 1,053 | 951.57 | 873.79 | 890.82 | 792.22 | 792.02 |
Gross Profit | 487.34 | 421.28 | 342.71 | 566.16 | 465.93 | 401.35 |
Selling, General & Admin | 216.27 | 218.15 | 213.97 | 248.85 | 193.53 | 169.96 |
Research & Development | 99.49 | 99.65 | 95.3 | 98.16 | 88.31 | 73.73 |
Other Operating Expenses | 23.97 | 8.88 | 0.95 | 14.46 | 11.49 | 5.73 |
Operating Expenses | 343.35 | 327.44 | 316.34 | 360.77 | 295.99 | 248.6 |
Operating Income | 143.99 | 93.84 | 26.36 | 205.4 | 169.94 | 152.75 |
Interest Expense | -66.7 | -48.27 | -29.06 | -27.45 | -27.08 | -23.79 |
Interest & Investment Income | 20.63 | 7.97 | 24.17 | 195.29 | 29.78 | 10.92 |
Currency Exchange Gain (Loss) | 12.48 | 12.48 | -3.45 | 15.52 | 3.2 | -10.81 |
Other Non Operating Income (Expenses) | -6.99 | -4.49 | -2.92 | -1.78 | 1.13 | -3.84 |
EBT Excluding Unusual Items | 103.42 | 61.53 | 15.1 | 386.99 | 176.97 | 125.23 |
Impairment of Goodwill | - | - | - | - | - | -28.26 |
Gain (Loss) on Sale of Investments | 10.17 | 4.84 | -18.33 | -6.24 | -5.23 | 99.01 |
Gain (Loss) on Sale of Assets | -1.38 | -1.08 | -9.34 | -20.31 | -6.17 | -2.14 |
Asset Writedown | -4.93 | - | - | - | -1.43 | - |
Other Unusual Items | 15.36 | 21.68 | 20.53 | 23.73 | 16.16 | 11.07 |
Pretax Income | 122.64 | 86.96 | 7.96 | 384.16 | 180.29 | 204.92 |
Income Tax Expense | 13.16 | 10.91 | -8.22 | 16.44 | 22.22 | 43.27 |
Earnings From Continuing Operations | 109.48 | 76.05 | 16.18 | 367.73 | 158.07 | 161.65 |
Minority Interest in Earnings | -10 | -9.24 | -4.6 | -28.87 | -15.54 | -5.69 |
Net Income | 99.48 | 66.81 | 11.59 | 338.86 | 142.53 | 155.96 |
Net Income to Common | 99.48 | 66.81 | 11.59 | 338.86 | 142.53 | 155.96 |
Net Income Growth | 390.12% | 476.63% | -96.58% | 137.75% | -8.62% | 3.35% |
Shares Outstanding (Basic) | 219 | 216 | 232 | 210 | 210 | 206 |
Shares Outstanding (Diluted) | 220 | 216 | 232 | 227 | 213 | 206 |
Shares Change (YoY) | -7.69% | -6.99% | 1.89% | 6.91% | 3.50% | 0.07% |
EPS (Basic) | 0.45 | 0.31 | 0.05 | 1.61 | 0.68 | 0.76 |
EPS (Diluted) | 0.45 | 0.31 | 0.05 | 1.49 | 0.67 | 0.76 |
EPS Growth | 430.94% | 520.00% | -96.64% | 122.39% | -11.70% | 2.92% |
Free Cash Flow | -73.34 | -81.87 | -210.41 | -294.67 | -309.26 | -88.16 |
Free Cash Flow Per Share | -0.33 | -0.38 | -0.91 | -1.30 | -1.45 | -0.43 |
Dividend Per Share | 0.050 | 0.050 | 0.020 | 0.165 | 0.142 | - |
Dividend Growth | 150.00% | 150.00% | -87.88% | 16.11% | - | - |
Gross Margin | 31.63% | 30.69% | 28.17% | 38.86% | 37.03% | 33.63% |
Operating Margin | 9.35% | 6.83% | 2.17% | 14.10% | 13.51% | 12.80% |
Profit Margin | 6.46% | 4.87% | 0.95% | 23.26% | 11.33% | 13.07% |
Free Cash Flow Margin | -4.76% | -5.96% | -17.30% | -20.22% | -24.58% | -7.39% |
EBITDA | 285.49 | 223.39 | 139.98 | 303.72 | 268.88 | 240.3 |
EBITDA Margin | 18.53% | 16.27% | 11.51% | 20.85% | 21.37% | 20.14% |
D&A For EBITDA | 141.5 | 129.55 | 113.62 | 98.32 | 98.94 | 87.54 |
EBIT | 143.99 | 93.84 | 26.36 | 205.4 | 169.94 | 152.75 |
EBIT Margin | 9.35% | 6.83% | 2.17% | 14.10% | 13.51% | 12.80% |
Effective Tax Rate | 10.73% | 12.55% | - | 4.28% | 12.33% | 21.12% |
Revenue as Reported | 1,541 | 1,373 | 1,216 | 1,457 | 1,258 | 1,193 |
Advertising Expenses | - | 25.77 | 19 | 21.52 | 9.14 | 1.14 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.